Intervacc AB announced that they have entered into an exclusive distribution agreement with Dechra Pharmaceuticals PLC, to commercialize Intervacc's leading vaccine candidate Strangvac in Europe, excluding the Nordic and Baltic countries where Intervacc will market and sell Strangvac directly. Strangvac is in late-stage regulatory review with the European Medicines Agency and is an innovative vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. The distribution agreement is based on Dechra purchasing finished products from Intervacc at an agreed transfer price plus additional future payments to Intervacc linked to pre-defined sales milestones.

The agreement will run for a period of five years and Intervacc will remain the Market Authorization holder for Strangvac in Europe. Intervacc is currently working with the European Medical Agency seeking approval for Strangvac in Europe and is forecasting approval in the second quarter of 2021.